Antifungal therapy – Page 17

Naganishia albidus Causing Perioral Cutaneous Infection: A Rare Case Easily Misdiagnosed

mycolabadmin

A 37-year-old construction worker developed unusual scaling and itchy sores around his mouth that worsened despite treatment for eczema. Doctors eventually discovered the infection was caused by a rare yeast fungus called Naganishia albidus, which is almost never seen in healthy people. Using advanced laboratory tests and antifungal medications taken by mouth and applied to the skin, the infection completely cleared within six weeks.

Fungal Δ9-fatty acid desaturase: a unique enzyme at the core of lipid metabolism in Aspergillus fumigatus and a promising target for the search for antifungal strategies

mycolabadmin

Certain dangerous fungal infections like aspergillosis are difficult to treat because current antifungal drugs have significant side effects or the fungi are developing resistance. Scientists have discovered that a specific enzyme called Δ9-fatty acid desaturase, which fungi need to make fats for their cell membranes, has a unique structure different from human cells. This structural difference offers a new opportunity to design antifungal drugs that could kill fungi without harming human cells, potentially providing safer and more effective treatments for serious fungal infections.

Extensive erythematous plaques of fungal origin in an overseas student: Cutaneous manifestation of coccidioidomycosis

mycolabadmin

A 21-year-old student studying in Arizona developed unusual skin rashes months after returning to China. Doctors had difficulty diagnosing the condition because it lacked typical symptoms of the fungal infection coccidioidomycosis. By using multiple diagnostic methods including DNA sequencing and fungal culture, they identified the infection as caused by Coccidioides posadasii. When the initial antifungal drug didn’t work, testing showed the fungus was resistant, so they switched to a different antifungal called voriconazole, which successfully cured the infection after 12 months.

Renaming Candida glabrata—A case of taxonomic purity over clinical and public health pragmatism

mycolabadmin

Candida glabrata is a common yeast infection that causes serious illnesses in humans, affecting millions of people worldwide. Scientists have recently proposed renaming it to Nakaseomyces glabrata for technical taxonomic reasons. However, this article argues against the change because it would create confusion for doctors, complicate treatment instructions on medications, disrupt disease tracking systems, and make it harder for patients to understand their conditions. Keeping the familiar name Candida glabrata is more practical and helpful for patient care and public health than strict adherence to taxonomic classification rules.

Chronic cavitary pulmonary histoplasmosis treated with isavuconazole after a hypersensitivity reaction to itraconazole

mycolabadmin

A 68-year-old patient with a serious lung infection caused by Histoplasma fungus initially developed an allergic skin reaction to the standard medication itraconazole. Unable to use the typical treatment, doctors switched him to a newer antifungal drug called isavuconazole using a carefully controlled graded dose approach. The patient successfully tolerated the new medication and achieved complete resolution of his infection with sustained improvement, suggesting isavuconazole could be a viable alternative for similar patients.

The Prognostic Value of (1→3)-β-D-Glucan in COVID-19 Patients with and Without Secondary Fungal Disease

mycolabadmin

During COVID-19, patients in intensive care sometimes develop dangerous fungal infections. Doctors use a blood test to measure a fungal marker called BDG to help diagnose these infections. This study found that even without confirmed fungal infection, high BDG levels predicted who would not survive, but giving antifungal medications improved survival even without proven infection.

Deep Fungal Infection of the Skin with Two Rare Fungi in a Dog Being Treated with Immunosuppressant Therapy: A Case Report

mycolabadmin

An 8-year-old dog receiving long-term immunosuppressive medication for brain inflammation developed rare fungal skin infections caused by two unusual fungi not previously reported together in veterinary medicine. Diagnosis required multiple tests including tissue samples, staining techniques, and genetic testing. Despite treatment with antifungal medications and careful adjustment of immunosuppressive drugs, the infections did not improve, highlighting the difficult balance between fighting infections and controlling the underlying immune disease.

Favorable outcome of Lasiodiplodia theobromae keratomycosis: a clinical case and systematic review

mycolabadmin

A 74-year-old farmer developed a serious fungal eye infection caused by Lasiodiplodia theobromae, a rare tropical fungus. Instead of requiring eye surgery, the patient was successfully treated with a combination of two antifungal medications applied as eye drops and taken orally for eight weeks. This case is significant because it’s the first documented successful medical treatment of this particular fungal infection, highlighting the importance of quick diagnosis and avoiding corticosteroid eye drops that can worsen fungal infections.

Successful management of Lomentospora prolificans septic arthritis and osteomyelitis in an immunocompetent child: A case report

mycolabadmin

A 3-year-old healthy child developed a serious fungal bone and joint infection in the elbow after surgery to repair a broken arm bone. The fungus, called Lomentospora prolificans, is extremely resistant to most medications and can lead to limb amputation. Doctors saved the child’s arm by combining multiple approaches: repeated surgeries to clean out infected tissue, three different antifungal medications taken together, special antibiotic-loaded bone cement placed in the elbow, and antiseptic wound washing. After six months of treatment, the infection was cured and the child could use their arm again.

Persistent Candidemia: Predictors and Outcomes in a Multicenter Matched Analysis

mycolabadmin

This study examined cases where fungal infections caused by Candida persisted in the bloodstream even after starting antifungal treatment. Researchers compared 46 patients with persistent infections to 92 control patients without persistent infections across three major medical centers. Patients with persistent candidemia were younger, more likely to be female, had more health complications, and sadly had much higher death rates (54% vs 31%) within 90 days. The findings suggest that certain patient characteristics and fungal species types may help identify those at higher risk of persistent infections.

Research Topic: Antifungal therapy